Top Markets
Coin of the day
MapLight Therapeutics, Inc. MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT
株式のランク #32258
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm... MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
株価
$13.43
最終同期: 2026-07-31
時価総額
$10.60M
変化(1日)
-4.26%
変化(1年)
-
US
取引 MapLight Therapeutics, Inc. (MPLT)

カテゴリー

MapLight Therapeutics, Inc.(MPLT)の配当利回りの履歴
MapLight Therapeutics, Inc.(銘柄コード: MPLT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
MapLight Therapeutics, Inc.(MPLT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)